Dead or Alive? Identification of Postmortem Blood Through Detection of D-Dimer
- PMID: 40723344
- PMCID: PMC12292195
- DOI: 10.3390/biology14070784
Dead or Alive? Identification of Postmortem Blood Through Detection of D-Dimer
Abstract
At crime scenes, apart from the detection of blood, it may be important to determine whether a person was alive at the time of blood deposition. Based on the rapid onset of fibrinolysis after death, this pathway could be considered to identify potential biomarkers for postmortem blood. Fibrinolysis is the natural process that breaks down blood clots after healing a vascular injury. One of its products, D-dimer, could be a potential biomarker for postmortem blood. SERATEC® (SERATEC® GmbH, Göttingen, Germany) has developed the PMB immunochromatographic assay to simultaneously detect human hemoglobin and D-dimer. The main goals of this study were to assess the possibility of using this test to detect postmortem blood, evaluate D-dimer levels in antemortem, menstrual, and postmortem blood, and assess the ability to obtain STR profiles from postmortem blood. Except for one degraded sample, all postmortem blood samples reacted positively for the presence of D-dimer using the SERATEC® PMB test. All antemortem blood samples from living individuals showed negative results for D-dimer detection, except for one liquid sample with a weak positive result, probably due to pre-existing health conditions. Menstrual blood samples gave variable results for D-dimer. The DIMERTEST® Latex assay was used for semi-quantitative measurement of D-dimer concentrations, with postmortem and menstrual blood yielding higher D-dimer concentrations compared to antemortem blood. Full STR profiles were developed for all postmortem samples tested except for one degraded sample, pointing to the possibility of not only detecting postmortem blood at the crime scene but also the potential identification of the victim.
Keywords: D-dimer; DNA profile; immunochromatographic test; menstrual blood; postmortem blood.
Conflict of interest statement
Authors Christian Stadler and Gabriela Roca are employed by the company SERATEC®. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.
Figures


Similar articles
-
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21. Clin Orthop Relat Res. 2025. PMID: 38905450
-
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263. doi: 10.1002/14651858.CD009263.pub2. Cochrane Database Syst Rev. 2015. PMID: 26417712 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
-
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Epidemiol Prev. 2013. PMID: 23851286 Italian.
References
Grants and funding
LinkOut - more resources
Full Text Sources